磁共振引导聚焦超声系统治疗子宫肌瘤新进展后的安全性及治疗量：一项队列研究
Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study.
作者信息
Quinn Stephen Derek, Vedelago John, Regan Lesley, Gedroyc Wladyslaw M
机构信息
Department of Obstetrics and Gynecology, St. Mary's Hospital, Imperial College London, South Wharf Road, London, UK.
Deparment of Radiology, St. Mary's Hospital, Imperial College London, Praed Street, London, UK.
出版信息
J Ther Ultrasound. 2013 Oct 1;1:20. doi: 10.1186/2050-5736-1-20. eCollection 2013.
BACKGROUND
This research investigates whether modifications to the magnetic resonance-guided focused ultrasound ablation of uterine fibroid (MRgFUS) system used resulted in improved treatment volumes of uterine fibroids, while maintaining safety.
METHODS
This study is a prospective cohort analysis of 34 women undergoing the ExAblate 2100 MRgFUS treatment for their uterine fibroids.
RESULTS
The percentage of non-perfused volume (NPV) achieved with the ExAblate 2100 system was 54.92% compared with 50.49 % with the ExAblate 2000 system over the preceding year (p = 0.543). The ExAblate 2100 system resulted in a greater NPV in hyper-intense fibroids compared with the ExAblate 200 system (43.20% versus 36.33%, p = 0.005). There have been no recorded hospital admissions, no skins burns, and no reported major adverse events since the introduction of this new system.
CONCLUSION
Overall, the new system has thus far shown an encouraging safety record and an improvement in non-perfused volumes achieved, especially in hyper-intense fibroids.
背景
本研究调查了对所用磁共振引导聚焦超声消融子宫肌瘤（MRgFUS）系统进行的改进是否在确保安全的同时提高了子宫肌瘤的治疗体积。
方法
本研究是一项对34名接受ExAblate 2100 MRgFUS治疗子宫肌瘤的女性进行的前瞻性队列分析。
结果
与上一年使用ExAblate 2000系统时的50.49%相比，ExAblate 2100系统实现的无灌注体积（NPV）百分比为54.92%（p = 0.543）。与ExAblate 200系统相比，ExAblate 2100系统在高强度肌瘤中产生了更大的NPV（43.20%对36.33%，p = 0.005）。自引入这一新系统以来，没有记录到住院情况，没有皮肤烧伤，也没有报告重大不良事件。
结论
总体而言，新系统迄今为止显示出令人鼓舞的安全记录，并且在实现的无灌注体积方面有所改善，尤其是在高强度肌瘤中。
Zotero 插件